AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment (AMS-INSIGHT1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00572494
Recruitment Status : Completed
First Posted : December 13, 2007
Last Update Posted : February 8, 2008
Biotronik SE & Co. KG
Information provided by:
Flanders Medical Research Program

Brief Summary:

Prospective, multicenter, randomized clinical trial, Follow-up at 1-, 6- and 12 months

This clinical investigation is first of all designed to demonstrate the safety and effectiveness of the MAGIC EXPLORER stent system. The primary objectives of the study are to evaluate the safety and 6-month patency of the bioabsorbable MAGIC EXPLORER stent in patients with stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries. Secondary endpoints are the procedural success, patency at all follow-ups, late lumen loss and limb-salvage rate. Peri-procedural complications (within 24 hours) will be evaluated. Furthermore, data of the balloon catheter PLEON EXPLORER will be collected to demonstrate its effectiveness and safety.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Device: MAGIC EXPLORER (Biotronik AG) Device: PLEON EXPLORER (Biotronik AG) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 117 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment
Study Start Date : July 2005
Actual Study Completion Date : January 2007

Arm Intervention/treatment
Experimental: 1
Stenting with AMS
Device: MAGIC EXPLORER (Biotronik AG)
The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
Active Comparator: 2
PTA alone
Device: PLEON EXPLORER (Biotronik AG)
The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.

Primary Outcome Measures :
  1. Efficacy : patency of the AMS, defined as the absence of a hemodynamically significant restenosis (> 50%) [ Time Frame: 6 month ]
  2. Safety: Complications at 1 month post-procedure (major amputations or any cause of death) [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Immediate angiographic procedural success, defined as maximal 30% residual stenosis on visual assessment of the planned treatment area. [ Time Frame: procedure ]
  2. Patency at follow-up visits determined with Color Flow Doppler Ultrasound (CFDU) [ Time Frame: 1 & 6 months ]
  3. Late lumen loss at 6 months. [ Time Frame: 6 months ]
  4. Limb-salvage rate at follow-up visits, defined as lack of major amputation. [ Time Frame: 1 & 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stenotic (> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
  • Length of lesion < 20mm (less than one stent length)
  • Reference vessel diameter should be 3.0-3.5 mm
  • A maximum of two lesions in one infrapopliteal vessel treated within the study, or in two vessels of two different legs. (PTA treatment of other infrapopliteal lesions in non-study vessels is allowed outside the study).
  • Symptomatic critical limb ischemia (Rutherford 4, 5)
  • The patient must be ≥ 50 years.
  • Life-expectancy of more than 6 months
  • The subject or legal guardian has been informed of the nature of the study; agrees to its provisions and has signed informed consent
  • The patient must be available for the appropriate follow-up times for the duration of the study
  • The patient is capable to follow all study requirements.

Exclusion Criteria:

  • Patient refusing treatment
  • The reference segment diameter is not suitable for available stent design
  • Length of lesion requires more than one stent implantation
  • Previously implanted stent(s) or PTA at the same lesion site
  • Lesion lies within or adjacent to an aneurysm
  • Inflow-limiting arterial lesions left untreated
  • The patient has a known allergy to heparin, Aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
  • The patient takes Phenprocoumon (Marcumar).
  • The patient has a history of prior life-threatening contrast media reaction.
  • The patient is currently enrolled in another investigational device or drug trial.
  • The patient is currently breast-feeding, pregnant or intends to become pregnant.
  • The patient is mentally ill or retarded.
  • The patient is liable for military or civilian service.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00572494

Medizinische Universität Graz
Graz, Austria
A.ö. Landeskrankenhaus Klagenfurt
Klagenfurt, Austria
Allgem. Krankenhaus Vienna
Vienna, Austria
Universitair Ziekenhuis Antwerpen
Antwerpen, Belgium
Imelda Ziekenhuis Bonheiden
Bonheiden, Belgium
AZ St-Blasius
Dendermonde, Belgium, 9200
Herzzentrum Bad Krozingen
Bad Krozingen, Germany
Humaine Kliniken Bad Saarow
Bad Saarow, Germany
Ev. Krankenhaus Herberge Berlin
Berlin, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Universitätsklinikum Mainz
Mainz, Germany
Sint-Elisabeth Ziekenhuis Tilburg
Tilburg, Netherlands
Sponsors and Collaborators
Flanders Medical Research Program
Biotronik SE & Co. KG
Principal Investigator: Marc Bosiers, MD AZ Sint-Blasius, Dendermonde, Belgium
Study Director: Evelyn Diessel, PhD Biotronik SE & Co. KG

Responsible Party: Marc Bosiers, MD, AZ Sint-Blasius hospital, Dendermonde, Belgium Identifier: NCT00572494     History of Changes
Other Study ID Numbers: BIOTRONIK Reference 27-1
Not available
First Posted: December 13, 2007    Key Record Dates
Last Update Posted: February 8, 2008
Last Verified: February 2008

Keywords provided by Flanders Medical Research Program:
Tibial arteries
Absorbable implants
Limb salvage

Additional relevant MeSH terms:
Peripheral Arterial Disease
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases